Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor of ErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors.
U. Keilholz
Honoraria - AstraZeneca
Research Funding - AstraZeneca
V. Moiseyenko
No relevant relationships to disclose
A. Makhson
Honoraria - Amgen; AstraZeneca; Lilly
V. Semiglazov
No relevant relationships to disclose
M. Learoyd
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
A. Saunders
Employment or Leadership Position - AstraZeneca
M. Stuart
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
S. Tjulandin
Consultant or Advisory Role - Novartis; Pfizer; Roche
Honoraria - AstraZeneca; GlaxoSmithKline; Sanofi